Guo Feng Huang

TL;DR: The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.

TL;DR: In vitro and in vivo properties of [(11)C]6-OH-BTA-1 support the choice of this derivative for further evaluation in human subject studies of brain Abeta deposition, and indicate the selective binding of the compound to amyloid plaques and cerebrovascular amyloids.

TL;DR: The combination of relatively high affinity for amyloid, specificity for staining plaques and neurofibrillary tangles in post-mortem AD brain, and good brain entry and clearance makes [N-methyl-11C]6-Me-BTA-1 a promising candidate as an in vivo positron emission tomography (PET) beta-sheet imaging agent.

TL;DR: Ex vivo brain pharmacokinetic and postmortem in vitro studies confirmed the low in vivo PIB retention observed in micro-PET experiments, and hypothesize that differences in the time course of deposition or tissue factors present during deposition lead to differences in secondary structure between Aβ deposited in AD brain and either synthetic Aβ or A β deposited in PS1/APP brain.

TL;DR: Amyloid deposits were imaged with multiphoton microscopy in the brains of living transgenic mice following the systemic injection of unlabeled 6, indicating that [(11)C]6 is a promising amyloid imaging agent for Alzheimer's disease.